1 Heart Failure: Executive Summary
1.1 The HF Market Will Exhibit Strong Growth Between 2022 and 2032
1.2 Label expansions of CV drugs will fuel market growth.
1.3 Unmet needs remain in the HF market despite the availability of well-established therapies.
1.4 Oral agents will dominate HF market.
1.5 What do physicians think?
2 Introduction
2.1 Catalyst
2.2 Related reports
3 Disease Overview
3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Biomarkers/Targets of interest
3.2 Classification or staging systems
3.3 Prognosis
4 Epidemiology
4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology.
4.4.1 Sources
4.4.2 Forecast assumptions and methods.
4.4.3 Forecast assumptions and methods: diagnosed incident cases of HF - 7MM.
4.4.4 Forecast assumptions and methods: diagnosed incident cases of HF by EF
4.4.5 Forecast assumptions and methods: hospitalizations for acute HF.
4.4.6 Forecast assumptions and methods: acute HF hospitalizations based on presentation.
4.4.7 Forecast assumptions and methods: hospital LoS days for acute HF hospitalizations.
4.4.8 Forecast assumptions and methods: re-admissions within 30 days post-discharge after acute HF hospitalization.
4.4.9 Forecast assumptions and methods: diagnosed prevalent cases of HF - 7MM.
4.4.10 Forecast assumptions and methods: diagnosed prevalent cases of HF by EF
4.4.11 Forecast assumptions and methods: diagnosed prevalent cases of HF by NYAH classes.
4.4.12 Forecast assumptions and methods: diagnosed prevalent cases of HF-PEF (LVEF=50%) NYHA Class
4.4.13 Forecast assumptions and methods: diagnosed prevalent cases of HF-mrEF (LVEF= 40-49%) NYHA class
4.4.14 Forecast assumptions and methods: diagnosed prevalent cases of HF-REF (LVEF < 40%) by NYHA class.
4.4.15 Forecast assumptions and methods: diagnosed prevalent cases of HF by ACCF/AHA stages.
4.5 Epidemiological forecast for heart failure (2022-32)
4.5.1 Diagnosed incident cases of HF.
4.5.2 Age-specific diagnosed incident cases of HF
4.5.3 Sex-specific diagnosed incident cases of HF
4.5.4 Diagnosed incident cases of HF by EF
4.5.5 Hospitalizations for acute HF
4.5.6 Acute HF hospitalizations based on presentation.
4.5.7 Hospital LoS for acute HF
4.5.8 Re-admissions within 30 days post-discharge after acute HF
4.5.9 Diagnosed prevalent cases of HF.
4.5.10 Age-specific diagnosed prevalent cases of HF
4.5.11 Sex-specific diagnosed prevalent cases of HF
4.5.12 Diagnosed prevalent cases of HF by EF
4.5.13 Diagnosed prevalent cases of HF by NYHA classes.
4.5.14 Diagnosed prevalent cases of HF-PEF (LVEF =50%) by NYHA class.
4.5.15 Diagnosed prevalent cases of HF-mrEF (LVEF = 40-49%) by NYHA class
4.5.16 Diagnosed prevalent cases of HF-REF (LVEF < 40%) by NYHA class
4.5.17 Diagnosed prevalent cases of HF by ACCF/AHA stages.
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact.
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis
5 Disease Management
5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Lack of therapies for HF-PEF patients
7.3 Lack of therapies for acute HF
7.4 Optimal management of HF treatments
7.5 Preventative therapies for patients at risk of developing HF.
8 R&D Strategies
8.1 Overview
8.1.1 Label expansion for therapies approved for other indications.
8.1.2 Mergers and acquisitions to expand product pipeline.
8.2 Clinical Trials Design
8.2.1 Clinical endpoints for HF
8.2.2 Inclusion and exclusion criteria
9 Pipeline Assessment
9.1 Overview
9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive assessment
11 Current and Future Players
11.1 Overview
11.2 Amgen and Cytokinetics
11.3 Bayer
11.4 Zensun
11.5 AstraZeneca
11.6 Boehringer Ingelheim
11.7 Lexicon
11.8 Johnson & Johnson
11.9 Viatris
11.10 CSL Vifor
11.11 Eli Lilly
11.12 Otsuka
11.13 Novartis
11.14 Novo Nordisk
11.15 Mesoblast
11.16 BioCardia
11.17 Deal-making trends
12 Market Outlook
12.1 Global markets
12.2 US
12.3 5EU
12.4 Japan
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary research - KOLs interviewed for this report.
13.4.1 KOLs
13.5 Primary research - prescriber survey
13.6 About the authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Vice President of Disease Intelligence and Epidemiology
List of Tables
Table 1: Heart failure: key metrics in the 7MM
Table 2: Types of chronic HF
Table 3: Causes of HF
Table 4: Compensatory mechanisms in HF patients
Table 5: Symptoms of heart failure
Table 6: Types of chronic HF
Table 7: Comparison of two HF classification systems
Table 8: Risk factors and comorbidities for HF
Table 9: Treatment guidelines for HF
Table 10: Amgen’s HF portfolio assessment, 2023
Table 11: Bayer’s HF portfolio assessment, 2023
Table 12: Zensun’s HF portfolio assessment, 2023
Table 13: AstraZeneca’s HF portfolio assessment, 2023
Table 14: Boehringer’s HF portfolio assessment, 2023
Table 15: Lexicon’s HF portfolio assessment, 2023
Table 16: Johnson & Johnson’s HF portfolio assessment, 2023
Table 17: Viatris’s HF portfolio assessment, 2023
Table 18: Vifor’s HF portfolio assessment, 2023
Table 19: Eli Lilly’s HF portfolio assessment, 2023
Table 20: Otsuka’s HF Portfolio Assessment, 2023
+S11Table 21: Novartis’s HF portfolio assessment, 2023
Table 22: Novo Nordisk’s HF portfolio assessment, 2023
Table 23: Mesoblast’s HF portfolio assessment, 2023
Table 24: BioCardia’s HF portfolio assessment, 2023
Table 25: Top 10 deals by value, 2018-2023
Table 26: HF market - global drivers and barriers, 2022-2032
Table 27: Key events impacting sales for HF in the US, 2022-2032
Table 28: HF market - drivers and barriers in the US, 2022-2032
Table 29: Key events impacting sales for HF in the 5EU, 2022-2032
Table 30: HF market - drivers and barriers in the 5EU, 2022-2032
Table 31: Key events impacting sales for HF in Japan, 2022-2032
Table 32: HF market - drivers and barriers in Japan, 2022-2032
Table 33: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: Global sales forecast by country for heart failure in 2022 and 2032
Figure 2: Analysis of the company portfolio gap in HF during the forecast period
Figure 3: Competitive assessment of the injectable late-stage pipeline agents that the publisher expects to be licensed for the treatment of HF during the forecast period
Figure 4: Competitive assessment of the oral late-stage pipeline agents that the publisher expects to be licensed for the treatment of HF during the forecast period
Figure 5: Changes in cardiac structure in HF
Figure 6: 7MM, diagnosed incidence of HF (cases per 100,000 population), men and women, all ages, 2022
Figure 7: 7MM, diagnosed prevalence of HF (%), men and women, all ages, 2022
Figure 8: 7MM, sources used and not used to forecast the diagnosed incident cases of HF
Figure 9: 7MM, sources used to forecast the diagnosed incident cases of HF by EF
Figure 10: 7MM, sources used to forecast the hospitalization for acute HF
Figure 11: 7MM, sources used to forecast the hospitalizations for acute HF by presentation
Figure 12: 7MM, sources used to forecast the hospital LoS for acute HF
Figure 13: 7MM, sources used to forecast the re-admissions within 30 days post-discharge after acute HF hospitalization
Figure 14: 7MM, sources used to forecast the diagnosed prevalent cases of HF
Figure 15: 7MM, sources used to forecast the diagnosed prevalent cases of HF by EF
Figure 16: 7MM, sources used to forecast the diagnosed prevalent cases of HF by NYHA class
Figure 15: 7MM, sources used to forecast the diagnosed prevalent cases of HF-PEF, HF-mrEF, and HF-REF by NYHA class
Figure 16: 7MM, sources used to forecast the diagnosed prevalent cases of HF by EF
Figure 17: 7MM, diagnosed incident cases of HF, N, both sexes, all ages, 2022
Figure 18: 7MM, diagnosed incident cases of HF by age, N, both sexes, 2022
Figure 19: 7MM, diagnosed incident cases of HF by sex, N, all ages, 2022
Figure 20: 7MM, diagnosed incident cases of HF by EF, N, both sexes, all ages, 2022
Figure 21: 7MM, hospitalizations for acute HF, N, both sexes, all ages, 2022
Figure 22: 7MM, acute HF hospitalizations based on presentation, N, both sexes, all ages, 2022
Figure 23: 7MM, hospital LoS for acute HF, days, both sexes, all ages, 2022
Figure 24: 7MM, re-admissions within 30 days post-discharge after acute HF hospitalization, N, both sexes, all ages, 2022
Figure 25: 7MM, diagnosed prevalent cases of HF, N, both sexes, all ages, 2022
Figure 26: 7MM, diagnosed prevalent cases of HF by age, N, both sexes, 2022
Figure 27: 7MM, diagnosed prevalent cases of HF by sex, N, all ages, 2022
Figure 28: 7MM, diagnosed prevalent cases of HF by sex, N, all ages, 2022
Figure 29: 7MM, diagnosed prevalent cases of HF by NYHA classes, N, both sexes, all ages, 2022
Figure 30: 7MM, diagnosed prevalent cases of HF-PEF (LVEF =50%) by NYHA class, N, both sexes, all ages, 2022
Figure 31: 7MM, diagnosed prevalent cases of HF-mrEF (LVEF = 40-49%) by NYHA class, N, both sexes, all ages, 2022
Figure 32: 7MM, diagnosed prevalent cases of HF-REF (LVEF < 40%) by NYHA class, N, both sexes, all ages, 2022
Figure 33: 7MM, diagnosed prevalent cases of HF by ACCF/AHA stages, N, both sexes, all ages, 2022
Figure 34: Diagnosis algorithm for chronic HF
Figure 35: Unmet needs and opportunities in chronic and acute heart failure
Figure 36: Overview of the development pipeline in heart failure
Figure 37: Key late-stage trials for the promising pipeline agents that the publisher expects be licensed for HF in the 7MM during the forecast period
Figure 38: Competitive assessment of the late-stage pipeline agents that the publisher expects to be licensed for the treatment of HF during the forecast period
Figure 39: Competitive assessment of the oral pipeline drugs benchmarked against the standard of care (SOC)
Figure 40: Competitive assessment of the injectable pipeline drugs benchmarked against the standard of care (SOC)
Figure 41: Analysis of the company portfolio gap in HF during the forecast period
Figure 42: Global (7MM) sales forecast by country for heart failure in 2022 and 2032
Figure 43: Sales forecast by class for heart failure in the US in 2022 and 2032
Figure 44: Sales forecast by class for heart failure in the 5EU in 2022 and 2032
Figure 45: Sales forecast by class for heart failure in Japan in 2022 and 2032
